Literature DB >> 23713484

Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial.

Bastian von Tresckow1, Boris Boell, Dennis Eichenauer, Denissa Beschorner, Stefan Knop, Maria-Elisabeth Goebeler, Jens Marcus Chemnitz, Michael Hallek, Andreas Engert, Kai Huebel.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23713484     DOI: 10.3109/10428194.2013.809074

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  2 in total

Review 1.  Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma.

Authors:  Maria Castella; Carlos Fernández de Larrea; Beatriz Martín-Antonio
Journal:  Int J Mol Sci       Date:  2018-11-15       Impact factor: 5.923

2.  Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis.

Authors:  Niels van Nieuwenhuijzen; Rowan Frunt; Anne M May; Monique C Minnema
Journal:  Blood Cancer J       Date:  2021-03-01       Impact factor: 11.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.